Faidra Laskou

Dr. Faidra Laskou


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2021 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
FLFaidra Laskou
Faidra Laskou
NFNicholas R. Fuggle
Nicholas R. Fuggle
HPHarnish P. Patel
Harnish P. Patel
KJKaren Jameson
Karen Jameson
CCCyrus Cooper
Cyrus Cooper
EDElaine Dennison
Elaine Dennison
Background: Ageing is commonly associated with sarcopenia (SP) and osteoporosis (OP), both of which are associated with disability, impaired quality of life, and mortality. The aims of this study were to explore the relationships between SP, OP, frailty, and multimorbidity in community‐dwelling older adults participating in the Hertfordshire Cohort Study (HCS) and to determine whether coexistence of OP and SP was associated with a significantly heavier health burden.Methods: At baseline, 405 participants self‐reported their comorbidities. Cut‐offs for low grip strength and appendicular lean mass index were used according to the EWSGOP2 criteria to define SP. OP was diagnosed when T‐scores of < −2.5 were present at the femoral neck or the participant reported use of the anti‐OP medications including hormone replacement therapy (HRT), raloxifene, or bisphosphonates. Frailty was defined using the standard Fried definition.Results: One hundred ninety‐nine men and 206 women were included in the study. Baseline median (interquartile range) age of participants was 75.5 (73.4–77.9) years. Twenty‐six (8%) and 66 (21.4%) of the participants had SP and OP, respectively. Eighty‐three (20.5%) reported three or more comorbidities. The prevalence of pre‐frailty and frailty in the study sample was 57.5% and 8.1%, respectively. Having SP only was strongly associated with frailty [odds ratio (OR) 8.28, 95% confidence interval (CI) 1.27, 54.03; P = 0.027] while the association between having OP alone and frailty was weaker (OR 2.57, 95% CI 0.61, 10.78; P = 0.196). The likelihood of being frail was substantially higher in the presence of coexisting SP and OP (OR 26.15, 95% CI 3.13, 218.76; P = 0.003). SP alone and OP alone were both associated with having three or more comorbidities (OR 4.71, 95% CI 1.50, 14.76; P = 0.008 and OR 2.86, 95% CI 1.32, 6.22; P = 0.008, respectively) although the coexistence of SP and OP was not significantly associated with multimorbidity (OR 3.45, 95% CI 0.59, 20.26; P = 0.171).Conclusions: Individuals living with frailty were often osteosarcopenic. Multimorbidity was common in individuals with either SP or OP. Early identification of SP and OP not only allows implementation of treatment strategies but also presents an opportunity to mitigate frailty risk.

26 July 2021 in Climacteric
Verified
Journal Article
Open access
FLFaidra Laskou
Faidra Laskou
HPH. P. Patel
H. P. Patel
CCC. Cooper
C. Cooper
EDE. Dennison
E. Dennison
The musculoskeletal conditions osteoporosis and sarcopenia are highly prevalent in older adults. Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone, whereas sarcopenia is identified by the loss of muscle strength, function and mass. Osteoporosis represents a major health problem contributing to millions of fractures worldwide on an annual basis, whereas sarcopenia is associated with a range of adverse physical and metabolic outcomes. They both affect physical and social function, confidence and quality of life as well as contributing to high health-care costs worldwide. Osteosarcopenia is the term given when both conditions occur concomitantly and it has been suggested that interactions between these two conditions may accelerate individual disease progression as co-existence of osteoporosis and sarcopenia is associated with higher morbidity from falls, fracture, disability as well as mortality. In this review, we will outline the epidemiology, pathogenesis and clinical consequences of osteosarcopenia and discuss available management strategies.

18 January 2020 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
GBGregorio Bevilacqua
Gregorio Bevilacqua
HDHayley J Denison
Hayley J Denison
FLFaidra Laskou
Faidra Laskou
KJKaren A. Jameson
Karen A. Jameson
KWKate A. Ward
Kate A. Ward
EDElaine Dennison
Elaine Dennison
Sleep duration may be associated with risk of osteoporosis, with suggestions that too little or indeed too much sleep may be detrimental to bone health. In this study, we considered whether perceived sleep quality is also associated with bone health in older adults. We explored this association in a cohort of 443 older community-dwelling UK adults. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI); poor sleep quality was defined as > 5 on this score system. Bone density, shape and microarchitecture were assessed using dual energy X-ray absorptiometry (DXA), peripheral quantitative computed tomography (pQCT) and high-resolution pQCT (HRpQCT). Thirty-seven percent of men and 43% of women had a PSQI score greater than 5, indicative of poor perceived sleep. We found that quality of sleep was associated with altered bone microarchitecture. In men, poor sleep quality was associated with lower radial trabecular (4% slice, p < 0.04) and cortical (66% slice, p = 0.02) bone mineral density, as well as decreased tibial cortical density (p < 0.02) and increased porosity (p < 0.04), but increased size of the tibia (p < 0.04). In women, poor perceived sleep quality was associated with thinner (p < 0.03) and less dense (p < 0.04) cortices of the radius, but greater tibial trabecular number (p < 0.02) and lower separation (p < 0.04). Relationships with DXA parameters were non-significant after adjustment for confounders. Taking sleep medications was associated with decreased tibial size (38% and 66% slices) and strength in women (all p < 0.05), but not in men. Perceived sleep quality was associated with altered bone density and microarchitecture in older adults, and these differences varied according to biological sex and site. Further work is indicated to investigate possible mechanisms underlying these observations.

8 April 2026 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
FLFaidra Laskou
Faidra Laskou
VKVictoria Konzett
Victoria Konzett
JSJosef S Smolen
Josef S Smolen
CEChristopher J Edwards
Christopher J Edwards
DADaniel Aletaha
Daniel Aletaha
AKAndreas Kerschbaumer
Andreas Kerschbaumer
This study aims to perform a systematic literature review (SLR) concerning the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the 2025 update of European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of rheumatoid arthritis (RA). Medline, Embase, Cochrane CENTRAL, and Web of Science were searched for observational and randomised controlled trials with a primary endpoint of DMARD safety on the conventional synthetic (cs-), biological (b-), and targeted synthetic-DMARDs, as well as glucocorticoids, published between January 14, 2022, and January 22, 2025. Separate searches on DMARD monitoring were conducted from database inception to January 22, 2025. A comparator group was required for inclusion. All safety outcomes were included. A total of 3837 articles were identified, with 321 selected for full-text review; 71 articles were included. Across the evidence base, infections were the most frequently assessed outcome: 13 studies examined serious or hospitalised infections, usually as composite endpoints of bacterial, opportunistic, and herpes zoster infection, while 1 addressed nonserious infections. Serious infections were more common with bDMARDs than csDMARDs. Janus kinase inhibitors (JAKis) showed a higher herpes zoster risk than bDMARDs. Tuberculosis risk was not increased with JAKis compared with bDMARDs, but was higher with infliximab and adalimumab compared with etanercept. Fifteen studies evaluated malignancy, split evenly between analyses of any malignancy and those excluding nonmelanoma skin cancer (NMSC); 2 focused on melanoma and 2 on NMSC. Increased NMSC was noted in patients with RA using DMARDs compared with the general population, with no link to a specific DMARD. Cardiovascular and thromboembolic events were reported in 20 studies. No consistent evidence of increased major adverse cardiovascular events risk with JAKis compared with bDMARDs was identified. Venous thromboembolism risk appeared elevated with JAKis compared with bDMARDs, driven mainly by pulmonary embolism. Fourteen studies reported retention and adverse event-related withdrawals, and 8 assessed other specific adverse events. Gastrointestinal perforation and demyelinating disease were each reported in 3 studies. No eligible articles were identified in searches on DMARD monitoring. There has been a notable increase in studies evaluating safety outcomes, with the majority of these being observational studies focusing primarily on malignancy, thromboembolic, and cardiovascular events, with most studies pertaining to JAKi safety. A substantial proportion of studies in this SLR relied on claims databases to evaluate safety outcomes, a practice that carries important methodological limitations for safety research. Surprisingly, not many studies looked into glucocorticoid safety outcomes over the past 3 years. This SLR, along with the SLR on efficacy of DMARDs, informed the 2025 update of the EULAR recommendations for management of RA with synthetic and biological DMARDs.

10 June 2022 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Open access
FLFaidra Laskou
Faidra Laskou
HPHarnish P. Patel
Harnish P. Patel
CCCyrus Cooper
Cyrus Cooper
EDElaine Dennison
Elaine Dennison
Bone and muscle are recognised as interacting tissues, the so-called 'muscle-bone unit', in which these two tissues communicate to coordinate their development (chemically and metabolically), as well as their response to loading or injury. Musculoskeletal disorders of ageing, specifically osteoporosis and sarcopenia, are highly prevalent in older individuals. They signify a significant burden for older people affecting their mobility, confidence, and quality of life, as well as being a major cost to healthcare systems worldwide. This review considers the coexistence of osteoporosis and sarcopenia in individuals and describes risk factors, clinical consequences, approaches to management, and the link with functional capacity.

9 September 2022 in Osteoarthritis and Cartilage Open
Verified
Journal Article
Open access
GBGregorio Bevilacqua
Gregorio Bevilacqua
FLFaidra Laskou
Faidra Laskou
HPHarnish P. Patel
Harnish P. Patel
LWLeo D. Westbury
Leo D. Westbury
NFNicholas R. Fuggle
Nicholas R. Fuggle
EDElaine Dennison
Elaine Dennison
Living independently remains the aim of older adults, but musculoskeletal conditions and frailty may hamper this. We examined relationships between osteoarthritis with ability to self-care and access to formal/informal care among community-dwelling older adults, comparing results to relationships between other musculoskeletal conditions of ageing (frailty, sarcopenia, osteoporosis) and these outcomes. Data from the Hertfordshire Cohort Study were used. Osteoarthritis (hand, hip or knee) was defined by clinical examination. Osteoporosis was assessed using dual-energy X-ray absorptiometry and medication use. Sarcopenia was assessed using EWSGOP2 criteria, frailty using Fried criteria. Ability to self-care and access to formal/informal care were self-reported. 443 men and women aged approximately 75 years participated. Osteoarthritis was reported by 26.8% participants; 11.8% had low grip strength; 21.4% had osteoporosis; 8.6% had sarcopenia; 7.6% were identified as frail. Most participants (90.7%) reported no problems with self-care, but more than one-fifth (21.4%) reported having received formal or informal care at home in the previous year. Odds of reporting difficulties with self-care were significantly greater (p ​< ​0.05) for participants with osteoarthritis and for those with frailty, but not for those with osteoporosis or sarcopenia. Odds of receiving care at home in the past year were significantly greater among participants with osteoarthritis and among those with frailty, but not among those with osteoporosis or sarcopenia. Frailty and osteoarthritis were associated with both difficulties with self-care and receipt of care; osteoporosis and sarcopenia were not. These results highlight the contribution of clinical osteoarthritis to ability to live independently in later life, and the need to actively manage the condition in older adults.